^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NK cell stimulant

    Related drugs:
    1m
    Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=51, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension • Platinum resistant
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    cyclophosphamide • fludarabine IV • TROP2-CAR-NK
    1m
    Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma (clinicaltrials.gov)
    P1, N=4, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 4 | Trial primary completion date: Dec 2026 --> Apr 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    UD TGFbetai NK cells
    1m
    An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy (clinicaltrials.gov)
    P1, N=36, Recruiting, Changhai Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • KN5501
    1m
    Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=60, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Aug 2026 --> May 2026
    Enrollment open • Trial initiation date • Pan tumor
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    cyclophosphamide • fludarabine IV
    1m
    Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P1, N=9, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression • DLL3 positive
    |
    cyclophosphamide • fludarabine IV
    2ms
    Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients. (PubMed, J Transl Med)
    This study provides a new strategy for enhancing the activity of DEXs derived from patients with MM, with the potential to develop DEXs as an antitumor vaccine for MM.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD80 (CD80 Molecule) • CD81 (CD81 Molecule) • CD86 (CD86 Molecule)
    |
    pomalidomide
    2ms
    NK521 in the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Base Therapeutics (Shanghai) Co., Ltd.
    New P1 trial
    2ms
    Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=8, Terminated, Second Affiliated Hospital of Xi'an Jiaotong University | N=34 --> 8 | Not yet recruiting --> Terminated; Achieved the proof of concept
    Enrollment change • Trial termination
    2ms
    Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial. (PubMed, Br J Haematol)
    Pretreatment CD4+ T-cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T-cell composition.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • dexamethasone • pomalidomide
    2ms
    Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=37, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Welireg (belzutifan)
    2ms
    Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pomalidomide
    2ms
    Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. (PubMed, Ann Med Surg (Lond))
    When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.
    Journal
    |
    CRBN (Cereblon)
    |
    Darzalex (daratumumab) • pomalidomide • forimtamig (RG6234)